KeyBanc raised the firm’s price target on ICU Medical to $147 from $136 and keeps an Overweight rating on the shares post Q2 on higher multiple/estimates. While there are still a few considerations for the second half of 2024, the firm was “broadly encouraged” by the magnitude of Q2 outperformance and it is tracking ahead of previous expectations.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ICUI: